Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
The Short on Competition Act amends the Federal Food, Drug, and Cosmetic Act to allow the Secretary of Health and Human Services to (1) temporarily authorize importation of prescription drugs for up to three years when there is or likely will be a drug shortage and certain conditions are met, and (2) designate "marginally competitive" drug markets as equivalent to shortages for the purpose of expedited generic review and temporary importation. The bill sets eligibility conditions for importation (same active ingredient, authorized in specified foreign countries, manufacturer intends to seek approval under 505(j), and an importer files attestations) and requires the Secretary to act within 60 days unless safety concerns justify denial.
Safety and regulatory oversight: liberals and centrists emphasize access plus strong oversight; conservatives emphasize limits on import authority and domestic supply resilience.
Relative to its intended legislative type, this bill is a substantive statutory change that is reasonably well-specified in defining when expedited approval and temporary importation can occur and how marginally competitive markets are determined.
The Short on Competition Act amends the Federal Food, Drug, and Cosmetic Act to allow the Secretary of Health and Human Services to (1) temporarily authorize importation of prescription drugs for up to three years when there is or likely will be a drug shortage and certain conditions are met, and (2) designate "marginally competitive" drug markets as equivalent to shortages for the purpose of expedited generic review and temporary importation.
The bill sets eligibility conditions for importation (same active ingredient, authorized in specified foreign countries, manufacturer intends to seek approval under 505(j), and an importer files attestations) and requires the Secretary to act within 60 days unless safety concerns justify denial.
It defines a marginally competitive market (fewer than five commercially available reference or generic drugs for at least two months, the reference listed drug approved at least 10 years earlier, and expired active-ingredient patents) and authorizes expedited review and inspections for such drugs.
Content-wise, this is a targeted, administratively focused bill with compromise features (time limits, safety denial, reporting) that improve prospects relative to sweeping reform. However, it alters pharmaceutical market dynamics via importation authority and expedited pathways—areas that frequently attract well-resourced opposition and significant policy debate. Without explicit funding or broad, built-in coalition incentives, the bill faces an uphill but not impossible path; success would likely require further negotiation, amendments, or packaging with other measures.
Relative to its intended legislative type, this bill is a substantive statutory change that is reasonably well-specified in defining when expedited approval and temporary importation can occur and how marginally competitive markets are determined. It integrates cleanly into the FD&C Act by amending and adding named sections and includes specific numeric and temporal thresholds.
Safety and regulatory oversight: liberals and centrists emphasize access plus strong oversight; conservatives emphasize limits on import authority and domestic supply resilience.
These are examples from the analysis, not a ranked list of the most-affected groups.
Safety and regulatory oversight: liberals and centrists emphasize access plus strong oversight; conservatives emphasize limits on import authority and domestic supply resilience.
A mainstream liberal/left-leaning observer would likely view the bill favorably as a targeted measure to increase competition, lower patient costs, and reduce shortages by allowing temporary importation and speeding generic approvals in thin markets.
They would appreciate that the authority is limited (temporary, tied to defined conditions, and requires manufacturer intent to seek 505(j) approval) and that reporting is required.
They would want strong safety oversight and protections against gaming by manufacturers but generally see the bill as a practical tool to reduce monopoly pricing and improve access.
A centrist/moderate observer would likely view the bill as a pragmatic, narrowly tailored policy to address specific problems: dangerously thin competition and drug shortages.
They would appreciate the time limits, conditions, and reporting requirements but would be cautious about rapid delegation of authority and possible operational hurdles for FDA.
Overall the centrists see potential public-benefit gains if safety is preserved and FDA is adequately funded to carry out expedited reviews and inspections.
A mainstream conservative observer would likely be skeptical of expanding temporary importation and the Secretary's discretionary authority, citing concerns about federal overreach, safety, and increased reliance on foreign supply chains.
They would note the bill increases executive discretion to treat market conditions as shortages and to expedite approvals and authorizations, which could be seen as an expansion of regulatory power.
Some conservatives might still view the focus on competition favorably if framed as market-opening, but many would insist on stronger safeguards for safety, domestic manufacturing, and limits on long-term dependence on imports.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Content-wise, this is a targeted, administratively focused bill with compromise features (time limits, safety denial, reporting) that improve prospects relative to sweeping reform. However, it alters pharmaceutical market dynamics via importation authority and expedited pathways—areas that frequently attract well-resourced opposition and significant policy debate. Without explicit funding or broad, built-in coalition incentives, the bill faces an uphill but not impossible path; success would likely require further negotiation, amendments, or packaging with other measures.
The bill has not accumulated any surfaced votes yet.
Safety and regulatory oversight: liberals and centrists emphasize access plus strong oversight; conservatives emphasize limits on import au…
Content-wise, this is a targeted, administratively focused bill with compromise features (time limits, safety denial, reporting) that impro…
Relative to its intended legislative type, this bill is a substantive statutory change that is reasonably well-specified in defining when expedited approval and temporary importation can occur and how marginally competi…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.